Drug Profile
Research programme: anticancer antibodies - MMRGlobal
Alternative Names: Anti-CD20 monoclonal antibodies - MMR Information Systems; Anti-CD20 monoclonal antibodies -MMRGlobalLatest Information Update: 07 Feb 2015
Price :
$50
*
At a glance
- Originator Diversa
- Developer MMRGlobal
- Class Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Non-Hodgkin's lymphoma
Most Recent Events
- 03 Feb 2015 MMRGlobal has patent protection for methods of treatment using the anti-CD20 monoclonal antibodies in USA
- 30 Nov 2011 Research programme: anticancer antibodies - MMR Information Systems is available for licensing as of 30 Nov 2011. http://www.mmrinformationsystems.com
- 15 Jun 2010 MMR Information Systems is now called MMRGlobal